Pfizer Inc.

Oncology and Hematologic Malignancies

Breast cancer, non-small cell lung cancer, small cell lung cancer, prostate cancer, and colorectal cancer are central areas of interest, alongside studies in ovarian cancer, head and neck squamous cell carcinoma, esophageal cancer, hepatocellular carcinoma, and bladder cancer. Research also extends to blood cancers such as multiple myeloma, diffuse large B-cell lymphoma, follicular lymphoma, acute lymphoblastic leukemia, and advanced lymphomas.

  • HER2-negative and hormone receptor-positive breast cancer
  • Advanced solid tumors
  • Relapsed or refractory multiple myeloma
  • Diffuse large B-cell lymphoma
  • Metastatic castration-resistant prostate cancer

Additional oncology work includes melanoma, non-muscle invasive bladder cancer, liposarcoma, and neuroblastoma, with a strong emphasis on advanced and metastatic disease settings.

Inflammatory and Autoimmune Disorders

Clinical research spans rheumatoid arthritis, systemic lupus erythematosus, cutaneous lupus erythematosus, idiopathic inflammatory myopathies, and juvenile idiopathic arthritis. The portfolio also includes immune-mediated skin and bowel diseases such as atopic dermatitis, alopecia areata, vitiligo, ulcerative colitis, Crohn’s disease, and eosinophilic esophagitis.

  • Atopic dermatitis
  • Vitiligo
  • Ulcerative colitis
  • Rheumatoid arthritis
  • Systemic lupus erythematosus

Other immune-focused studies address chronic spontaneous urticaria, hidradenitis suppurativa, and immune-mediated inflammatory disorders affecting skin, joints, and gastrointestinal tissues.

Hematology, Bleeding Disorders, and Cardiovascular Disease

Key hematology programs involve hemophilia A, hemophilia B, and primary immune thrombocytopenia, with attention to inherited bleeding disorders across pediatric and adult populations. Cardiovascular research includes heart failure, heart failure with preserved ejection fraction, and pulmonary arterial hypertension.

  • Hemophilia A
  • Hemophilia B
  • Primary immune thrombocytopenia
  • Heart failure with preserved ejection fraction
  • Pulmonary arterial hypertension

Additional areas include transthyretin amyloidosis and transthyretin amyloid cardiomyopathy, reflecting interest in rare cardiovascular and systemic protein-aggregation disorders.

Infectious Diseases and Vaccines

Pfizer’s infectious disease portfolio includes studies in COVID-19, RSV infection, pneumococcal infections, group B streptococcus disease, and serious gram-negative bacterial infections. Research also covers hospital-acquired pneumonia, ventilator-associated pneumonia, sepsis, and complicated urinary tract infection.

  • Respiratory syncytial virus
  • Group B streptococcus
  • Pneumococcal disease
  • Gram-negative bacterial infections
  • COVID-19

Vaccine-oriented work includes maternal and infant immunization studies, with emphasis on neonatal protection and prevention of invasive bacterial and respiratory infections.

Neurology, Metabolic, and Other Therapeutic Areas

Neurology studies focus on migraine, including chronic migraine, menstrual migraine, and migraine with or without aura, as well as prevention in adolescents. Metabolic and supportive-care research includes obesity, overweight management, type 2 diabetes mellitus, and cancer cachexia.

  • Migraine disorders
  • Obesity and overweight management
  • Type 2 diabetes mellitus
  • Cancer cachexia
  • Growth hormone deficiency

Other areas of interest include duchenne muscular dystrophy, IgA nephropathy, obesity-related appetite loss, and erosive esophagitis, showing breadth across neuromuscular, renal, gastrointestinal, and metabolic conditions.

Want to learn more about this study or check if you can participate? Contact us.

Matched clinical trials

  • Study of Palbociclib with Drug Combinations for Children and Young Adults with Recurrent or Refractory Neuroblastoma and Ewing Sarcoma

    Not recruiting

    1 1 1 1
    Czechia France Germany Slovakia Sweden
  • Study of Encorafenib and Binimetinib for Patients with BRAF V600-Mutant Non-Small Cell Lung Cancer

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy The Netherlands Spain
  • Study of Elranatamab for Patients with Multiple Myeloma Resistant to Proteasome Inhibitors, Immunomodulatory Drugs, and Anti-CD38 Antibodies

    Not recruiting

    2 1 1
    Investigated drugs:
    Belgium France Germany Poland Spain
  • Study on Elranatamab and Daratumumab for Patients with Relapsed or Refractory Multiple Myeloma After Prior Treatment

    Not recruiting

    3 1 1 1
    Austria Belgium Czechia Finland France Germany +7
  • Study on the Safety and Effectiveness of Vepdegestrant and Samuraciclib for Adults with ER+ Advanced or Metastatic Breast Cancer

    Not recruiting

    1 1 1
    Belgium France Italy Spain
  • Study of Ritlecitinib (50 mg and 100 mg daily) compared to placebo in adults with nonsegmental vitiligo

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Bulgaria Germany Hungary Italy Poland +2